5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
There O
have O
been O
postmarketing O
reports O
of O
acute O
pancreatitis O
, O
including O
fatal O
pancreatitis O
. O

If O
pancreatitis O
is O
suspected O
, O
promptly O
discontinue O
TRADJENTA O
. O

( O
5.1 O
) O
* O
When O
used O
with O
an O
insulin O
secretagogue O
( O
e.g. O
, O
sulfonylurea O
) O
or O
insulin O
, O
consider O
lowering O
the O
dose O
of O
the O
insulin O
secretagogue O
or O
insulin O
to O
reduce O
the O
risk O
of O
hypoglycemia O
( O
5.2 O
) O
* O
There O
have O
been O
postmarketing O
reports O
of O
serious O
hypersensitivity O
reactions O
in O
patients O
treated O
with O
TRADJENTA O
including O
anaphylaxis O
, O
angioedema O
, O
and O
exfoliative O
skin O
conditions O
. O

In O
such O
cases O
, O
promptly O
discontinue O
TRADJENTA O
, O
assess O
for O
other O
potential O
causes O
, O
institute O
appropriate O
monitoring O
and O
treatment O
, O
and O
initiate O
alternative O
treatment O
for O
diabetes O
. O

( O
5.3 O
) O
* O
Severe O
and O
disabling O
arthralgia O
has O
been O
reported O
in O
patients O
taking O
DPP-4 O
inhibitors O
. O

Consider O
as O
a O
possible O
cause O
for O
severe O
joint O
pain O
and O
discontinue O
drug O
if O
appropriate O
. O

( O
5.4 O
) O
* O
There O
have O
been O
no O
clinical O
studies O
establishing O
conclusive O
evidence O
of O
macrovascular O
risk O
reduction O
with O
TRADJENTA O
or O
any O
other O
antidiabetic O
drug O
( O
5.5 O
) O
5.1 O
Pancreatitis O
There O
have O
been O
postmarketing O
reports O
of O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
including O
fatal B-NonOSE_AE
pancreatitis B-OSE_Labeled_AE
, O
in O
patients O
taking O
TRADJENTA O
. O

Take O
careful O
notice O
of O
potential O
signs O
and O
symptoms O
of O
pancreatitis B-NonOSE_AE
. O

If O
pancreatitis B-NonOSE_AE
is O
suspected O
, O
promptly O
discontinue O
TRADJENTA O
and O
initiate O
appropriate O
management O
. O

It O
is O
unknown O
whether O
patients O
with O
a O
history O
of O
pancreatitis B-Not_AE_Candidate
are O
at O
increased O
risk O
for O
the O
development O
of O
pancreatitis B-NonOSE_AE
while O
using O
TRADJENTA O
. O

5.2 O
Use O
with O
Medications O
Known O
to O
Cause O
Hypoglycemia O
Insulin O
secretagogues O
and O
insulin O
are O
known O
to O
cause O
hypoglycemia B-NonOSE_AE
. O

The O
use O
of O
TRADJENTA O
in O
combination O
with O
an O
insulin O
secretagogue O
( O
e.g. O
, O
sulfonylurea O
) O
was O
associated O
with O
a O
higher O
rate O
of O
hypoglycemia B-NonOSE_AE
compared O
with O
placebo O
in O
a O
clinical O
trial O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
use O
of O
TRADJENTA O
in O
combination O
with O
insulin O
in O
subjects O
with O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
was O
associated O
with O
a O
higher O
rate O
of O
hypoglycemia B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Therefore O
, O
a O
lower O
dose O
of O
the O
insulin O
secretagogue O
or O
insulin O
may O
be O
required O
to O
reduce O
the O
risk O
of O
hypoglycemia B-NonOSE_AE
when O
used O
in O
combination O
with O
TRADJENTA O
. O

5.3 O
Hypersensitivity O
Reactions O
There O
have O
been O
postmarketing O
reports O
of O
serious O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in O
patients O
treated O
with O
TRADJENTA O
. O

These O
reactions O
include O
anaphylaxis B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
and O
exfoliative B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
conditions I-OSE_Labeled_AE
. O

Onset O
of O
these O
reactions O
occurred O
within O
the O
first O
3 O
months O
after O
initiation O
of O
treatment O
with O
TRADJENTA O
, O
with O
some O
reports O
occurring O
after O
the O
first O
dose O
. O

If O
a O
serious O
hypersensitivity B-NonOSE_AE
reaction I-NonOSE_AE
is O
suspected O
, O
discontinue O
TRADJENTA O
, O
assess O
for O
other O
potential O
causes O
for O
the O
event O
, O
and O
institute O
alternative O
treatment O
for O
diabetes B-Not_AE_Candidate
. O

Angioedema B-NonOSE_AE
has O
also O
been O
reported O
with O
other O
dipeptidyl O
peptidase-4 O
( O
DPP-4 O
) O
inhibitors O
. O

Use O
caution O
in O
a O
patient O
with O
a O
history O
of O
angioedema B-Not_AE_Candidate
to O
another O
DPP-4 O
inhibitor O
because O
it O
is O
unknown O
whether O
such O
patients O
will O
be O
predisposed O
to O
angioedema B-NonOSE_AE
with O
TRADJENTA O
. O

5.4 O
Severe O
and O
Disabling O
Arthralgia O
There O
have O
been O
postmarketing O
reports O
of O
severe O
and O
disabling O
arthralgia B-OSE_Labeled_AE
in O
patients O
taking O
DPP-4 O
inhibitors O
. O

The O
time O
to O
onset O
of O
symptoms O
following O
initiation O
of O
drug O
therapy O
varied O
from O
one O
day O
to O
years O
. O

Patients O
experienced O
relief O
of O
symptoms O
upon O
discontinuation O
of O
the O
medication O
. O

A O
subset O
of O
patients O
experienced O
a O
recurrence O
of O
symptoms O
when O
restarting O
the O
same O
drug O
or O
a O
different O
DPP-4 O
inhibitor O
. O

Consider O
DPP-4 O
inhibitors O
as O
a O
possible O
cause O
for O
severe O
joint B-NonOSE_AE
pain I-NonOSE_AE
and O
discontinue O
drug O
if O
appropriate O
. O

5.5 O
Macrovascular O
Outcomes O
There O
have O
been O
no O
clinical O
studies O
establishing O
conclusive O
evidence O
of O
macrovascular B-NonOSE_AE
risk I-NonOSE_AE
reduction O
with O
TRADJENTA O
tablets O
or O
any O
other O
antidiabetic O
drug O
. O

